Titre :

Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.

Auteur(s) :

Brouillard-Saby, F. [Auteur]
Institut Curie [Paris]
Saint-Martin, C. [Auteur]
Institut Curie [Paris]
Ray-Coquard, Isabelle [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Department of Medical Oncology [Lyon]
Centre Léon Bérard [Lyon]
Health Service and Performance Research [HESPER]
Gladieff, Laurence [Auteur]
Institut Claudius Regaud [ICR]
Département d'oncologie médicale
Pomel, C. [Auteur]
Imagerie Moléculaire et Stratégies Théranostiques [IMoST]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Colombo, P. E. [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Classe, J. M. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Chevrier, M. [Auteur]
Institut Curie [Paris]
Joly, Florence [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Service d'Oncologie médicale [CHU Caen]
De La Motte Rouge, T. [Auteur]
CRLCC Eugène Marquis [CRLCC]
Floquet, Anne [Auteur]
Institut Bergonié [Bordeaux]
Sabatier, R. [Auteur]
Institut Paoli-Calmettes [IPC]
Barranger, E. [Auteur]
Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] [UNICANCER/CAL]
Costaz, H. [Auteur]
Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] [UNICANCER/CRLCC-CGFL]
Leblanc, Eric [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Marchal, F. [Auteur]
Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] [UNICANCER/ICL]
Pautier, Patricia [Auteur]
Institut Gustave Roussy [IGR]
Bosquet, L. [Auteur]
Rodrigues, M. [Auteur]
Institut Curie [Paris]
Unité de génétique et biologie des cancers [U830]

Titre de la revue :

International Journal of Gynecological Cancer

Nom court de la revue :

Int J Gynecol Cancer

Date de publication :

2023-01-12

ISSN :

1525-1438

Mot(s)-clé(s) en anglais :

Gynecology
Ovarian Cancer
Neoplasm Recurrence
Local
Cystadenocarcinoma
Serous
BRCA1 Protein

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objective Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to in vitro ...
Lire la suite >Objective Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to in vitro data, BRCA mutated patients are sensitive to replicative stress agents but BRCA status is not yet used for the choice of chemotherapy at relapse. Our aim was to assess these doublets according to BRCA status in first platinum-sensitive relapse. Methods The ESME ovarian cancer database comprises a multicenter retrospective cohort of patients with ovarian cancer treated in French cancer centers between January 2011 and December 2017. Patients with high-grade serous ovarian cancers at first platinum-sensitive relapse who received one of these doublets were included. The objective was to compare progression-free survival of each chemotherapy doublet according to BRCA status. Results Among the 10 263 patients in the database, 1539 patients had a first platinum-sensitive relapse: 825 BRCA wild type patients (53.6%) and 304 BRCA mutated patients (19.8%) (7 patients had a homologous recombination mutation and BRCA status was unkown for 403 patients). Median progression-free survival was longer in BRCA mutated patients than in BRCA wild type patients when receiving carboplatin/pegylated liposomal doxorubicin without maintenance treatment (15.8 vs 11.8 months; p<0.001). In contrast, we observed no difference in patients treated with carboplatin/paclitaxel (14.6 vs 14.3 months, respectively; p=0.70) or in those treated with carboplatin/gemcitabine (12.0 vs 9.8 months, respectively; p=0.18). In BRCA wild type patients without maintenance, better progression-free survival occurred with carboplatin/paclitaxel (median progression-free survival 14.3 months) than with carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin (9.8 and 11.8 months, respectively; p=0.017). In BRCA mutated patients without maintenance, there was no difference between the three doublets (median progression-free survival of 14.6, 12.0, and 15.8 months with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin, respectively; p=0.40). Conclusion While treatment with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin shows comparable efficacy in BRCA mutated patients, treatment with carboplatin/paclitaxel appears to be more effective than carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin in BRCA wild type patients with high-grade serous ovarian cancers at first platinum-sensitive relapse.Lire moins >

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2023-12-13T03:53:27Z
2024-01-31T15:48:50Z